During the past decade, Retina-Vitreous Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Retina-Vitreous Associates" are "Diabetic Retinopathy" (1 trials), "Macular Degeneration" (1 trials) and "Vitreous Hemorrhage" (1 trials). Many other conditions were trialed in "Retina-Vitreous Associates" in a lesser frequency.

Most popular intervention types in "Retina-Vitreous Associates" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Vitrase" (1 trials) and "rhuFab V2 (ranibizumab)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Retina-Vitreous Associates" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Retina-Vitreous Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Retina-Vitreous Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Retina-Vitreous Associates, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".